MAPT and Alzheimer disease: It has been shown numerously that the relative risk of progression to dementia is considerably higher in patients with MCI who have typical AD biomarker measurements, namely increased total-Tau and lowered Aβ 1–42 (15, 16, 17, 18, 19).